SIGA Technologies (SIGA): Examining Valuation After Monkeypox Market Growth Projections Drive Investor Interest

Simply Wall St.10-29

Recent coverage of the monkeypox treatment market projects it will reach $258 million by 2032, growing 18% yearly. SIGA Technologies (SIGA) stands out as a key player, as demand rises alongside global...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579970929?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2025-10-29 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579970929","market":"us","top_or_hot":-1,"title":"SIGA Technologies (SIGA): Examining Valuation After Monkeypox Market Growth Projections Drive Investor Interest","media":"Simply Wall St.","content":"<div>\n<p>Recent coverage of the monkeypox treatment market projects it will reach $258 million by 2032, growing 18% yearly. SIGA Technologies (SIGA) stands out as a key player, as demand rises alongside global...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-siga/siga-technologies/news/siga-technologies-siga-examining-valuation-after-monkeypox-m\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIGA Technologies (SIGA): Examining Valuation After Monkeypox Market Growth Projections Drive Investor Interest</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIGA Technologies (SIGA): Examining Valuation After Monkeypox Market Growth Projections Drive Investor Interest\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-29 18:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-siga/siga-technologies/news/siga-technologies-siga-examining-valuation-after-monkeypox-m><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recent coverage of the monkeypox treatment market projects it will reach $258 million by 2032, growing 18% yearly. SIGA Technologies (SIGA) stands out as a key player, as demand rises alongside global...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-siga/siga-technologies/news/siga-technologies-siga-examining-valuation-after-monkeypox-m\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4583","symbol_name":"猴痘概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-siga/siga-technologies/news/siga-technologies-siga-examining-valuation-after-monkeypox-m","article_id":"2579970929","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-siga/siga-technologies/news/siga-technologies-siga-examining-valuation-after-monkeypox-m","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2579970929","pubTimestamp":1761733262,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent coverage of the monkeypox treatment market projects it will reach $258 million by 2032, growing 18% yearly. SIGA Technologies (SIGA) stands out as a key player, as demand rises alongside global monkeypox cases.\nSee our latest analysis for SIGA Technologies.\nSIGA Technologies has seen its share price swing higher, now sitting at $8.44. The company has posted a robust 90-day share price return of 26.5% and a year-to-date move of 35.3% as investor optimism builds around the growing...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4583":"猴痘概念","SIGA":"SIGA Technologies Inc","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4007":"制药"},"translate_title":"SIGA Technologies(SIGA)：猴痘市场增长预测激发投资者兴趣后审查估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SIGA":1.5,"DCF":1},"content_text":"Recent coverage of the monkeypox treatment market projects it will reach $258 million by 2032, growing 18% yearly. SIGA Technologies (SIGA) stands out as a key player, as demand rises alongside global monkeypox cases. See our latest analysis for SIGA Technologies. SIGA Technologies has seen its share price swing higher, now sitting at $8.44. The company has posted a robust 90-day share price return of 26.5% and a year-to-date move of 35.3% as investor optimism builds around the growing monkeypox market. Despite a dip over the last month, shareholders are up more than 31% over the past year when accounting for total returns. This suggests momentum is still very much in play for both the short and long term. If new momentum in the infectious disease space has you looking for what's next, consider broadening your search and discover See the full list for free. With SIGA’s strong gains and the market’s bullish outlook, the big question for investors is whether shares are still undervalued or if the future growth is already reflected in the current price. Could there still be a buying opportunity? AdvertisementPrice-to-Earnings of 7.4x: Is it justified? SIGA is priced at a 7.4x price-to-earnings multiple, which is substantially below the US Pharmaceuticals industry average of 17.3x and the peer average of 30.6x. With the stock closing at $8.44, this signals a notable discount despite strong recent performance. The price-to-earnings (P/E) ratio measures what investors are willing to pay today for a dollar of future earnings. For a pharmaceutical company experiencing high demand and showing strong margins, a low P/E can highlight either market skepticism or a potential value opportunity. SIGA’s low P/E ratio appears increasingly attractive given its quality earnings and ambitious growth forecasts. Compared to the industry average and an estimated “fair” P/E of 21.2x, the market could be underappreciating future potential. If SIGA’s projected growth materializes, market multiples may move closer to these higher levels. Explore the SWS fair ratio for SIGA Technologies Result: Price-to-Earnings of 7.4x (UNDERVALUED) However, investors should remain alert to challenges such as unpredictable regulatory shifts or sudden declines in infectious disease outbreaks, which could temper growth expectations. Find out about the key risks to this SIGA Technologies narrative. Another View: What Does Our DCF Say? Looking at SIGA Technologies through the lens of the SWS DCF model gives a dramatically different picture. In this case, the estimated fair value comes in much higher than the current share price. This suggests the stock is sharply undervalued. However, the big gap may be an actionable opportunity or an indication to investigate further. Look into how the SWS DCF model arrives at its fair value. SIGA Discounted Cash Flow as at Oct 2025Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out SIGA Technologies for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own SIGA Technologies Narrative If you have a different perspective or want to dig deeper into the numbers, you can construct your own view of SIGA Technologies in just a few minutes, and Do it your way. A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding SIGA Technologies. Looking for more investment ideas? Don’t stop with just one stock. Experts know lasting gains often come from uncovering the next big opportunity first. If you want every edge, take action now:  Tap into the growing demand for reliable income by checking out these 21 dividend stocks with yields > 3%, which offers attractive yields and stability. Stay ahead of tech trends and unlock high-growth potential in artificial intelligence by searching through these 26 AI penny stocks, which are moving markets right now. Capitalize on undervalued gems that the market may have missed. See if any stand out to you among these 869 undervalued stocks based on cash flows.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579970929","isCrawlerRequest":true}